(Foundation News/Usher Syndrome)
... of very low concentrations of potential impurities in material used to make the treatments. The clinical trials impacted by this action are for RetinoStat®, StarGen™ and UshStat®, potential therapies for ...
(Funded Grants/Uncategorized)
... Omaha, NE $65,000 Dr. Cosgrove performed lab studies of a gene therapy for Usher syndrome type 1B in support of Oxford BioMedica’s UshStat® gene therapy clinical trial. Code=4 Jeffrey Chulay, M.D. ...
(Foundation News/Usher Syndrome)
... a leading gene therapy development company in the United Kingdom, has received a positive interim safety review of its ongoing Phase I/IIa clinical trial for the UshStat® gene therapy for people with Usher ...
(Foundation News/Usher Syndrome)
... the Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, a clinical trial site for UshStat®, a gene therapy developed by Oxford BioMedica for people with Usher syndrome type 1B (USH1B). The funding ...
(Foundation News/Stargardt Disease)
... — StarGen™ for Stargardt disease and UshStat® for Usher syndrome type 1B — has received a major boost. Sanofi, a large international pharmaceutical company, has licensed the treatments from Oxford BioMedica, ...
(Foundation News/Usher Syndrome)
... partner, the UshStat® treatment is designed to halt vision loss in people affected with Usher syndrome type 1B, which is caused by defects in the MY07A gene. Based on results in lab studies, researchers ...
(Clinical Trials/Usher Syndrome)
Description: Oxford BioMedica, a gene therapy company in the U.K., has launched a Phase I/IIa clinical trial of its UshStat® gene therapy for people with Usher syndrome type 1B. The trial has received ...
(Foundation News/Usher Syndrome)
A clinical trial of UshStat®, the first-ever gene therapy for Usher syndrome type 1B, is on track to begin by the end of 2011, thanks to the FDA’s approval of the Investigative New Drug application submitted ...
(Foundation News/Stargardt Disease)
... 1.7 million people in the U.S. and millions more in other developed countries have wet AMD. Oxford BioMedica is expecting to begin a Phase I/IIa clinical trial of its UshStat® gene therapy at OHSU and ...
(Foundation News/Stargardt Disease)
... of the ABCR gene. In addition to StarGen™, the Foundation Fighting Blindness has been partnering with Oxford BioMedica in its development of UshStat™ gene therapy for the treatment of Usher syndrome ...
(Foundation News/Macular Degeneration)
... organization has been partnering with Oxford Biomedica in its development of StarGen™ gene therapy for the treatment of Stargardt disease and UshStat® gene therapy for Usher syndrome 1B. The Foundation ...
(Foundation News/Usher Syndrome)
... as UshStat. The orphan designation provides Oxford BioMedica with benefits and incentives including 10 years of marketing exclusivity, reduced regulatory fees, and clinical development guidance for UshStat. ...
(Foundation News/Macular Degeneration)
... of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Other Retinal Diseases)
... of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Retinitis Pigmentosa)
... of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Stargardt Disease)
... of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Usher Syndrome)
... of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(News & Events/Press Releases)
... for the treatment of Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; RetinoStat® for the treatment of age-related ...
(Foundation News/Macular Degeneration)
... Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Other Retinal Diseases)
... Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Stargardt Disease)
... Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Foundation News/Usher Syndrome)
... Stargardt disease, a form of early-onset macular degeneration; UshStat™ for the treatment of Usher syndrome, the leading cause of deaf-blindness; and RetinoStat® for the treatment of age-related macular ...
(Section)
... performed lab studies of a gene therapy for Usher syndrome type 1B in support of Oxford BioMedica’s UshStat® gene therapy clinical trial. Jeffrey Chulay, M.D. Applied Genetics Technologies Corp. Alachua, ...
